Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
1. 7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo(1,2-a)pyrido(3,4-e)pyrimidin-5(4h)-one
2. Onc201
3. Tic10 Compound
4. Trail-inducing Compound 10
1. 1616632-77-9
2. Onc 201
3. Onc-201
4. Onc201
5. Nsc-350625
6. 9u35a31jai
7. Mfcd28118993
8. 11-benzyl-7-[(2-methylphenyl)methyl]-2,5,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5-dien-8-one
9. 1342897-86-2
10. Active Isomer 2
11. Tic10 Compound
12. 7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo(1,2-a)pyrido(3,4-e)pyrimidin-5(4h)-one
13. Angular Tic10
14. Tic10 Active Isomer
15. Unii-9u35a31jai
16. Gtpl9978
17. Tic10?
18. Chembl4297310
19. Onc 201 [who-dd]
20. Schembl16227974
21. Ex-a669
22. Hms3874g13
23. Bcp14991
24. Hy-15615a
25. Nsc784931
26. S7963
27. Zinc169620396
28. Ccg-264705
29. Cs-3564
30. Db14844
31. Nsc 350625
32. Nsc-784931
33. Sb17110
34. Ncgc00386747-03
35. Ncgc00386747-06
36. Ncgc00386747-09
37. Ncgc00386747-10
38. As-16735
39. Sy242153
40. Ft-0700231
41. A883070
42. J-690224
43. Q27895916
44. 2,4,6,7,8,9-hexahydro-4-((2-methylphenyl)methyl)-7-(phenylmethyl)imidazo(1,2-a)pyrido(3,4-e)pyrimidin-5(1h)-one
45. 2,4,6,7,8,9-hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimidin-5(1h)-one
Molecular Weight | 386.5 g/mol |
---|---|
Molecular Formula | C24H26N4O |
XLogP3 | 2.3 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 4 |
Exact Mass | 386.21066147 g/mol |
Monoisotopic Mass | 386.21066147 g/mol |
Topological Polar Surface Area | 39.2 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 693 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Details:
Through the acquisition, Jazz will strengthen it's oncology pipeline, which includes ONC201 (dordaviprone). It is being evaluated in the late-stage for the treatment of H3 K27M-mutant diffuse glioma.
Lead Product(s): Dordaviprone,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Jazz Pharmaceuticals
Deal Size: $935.0 million Upfront Cash: $935.0 million
Deal Type: Acquisition April 21, 2025
Lead Product(s) : Dordaviprone,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Jazz Pharmaceuticals
Deal Size : $935.0 million
Deal Type : Acquisition
Jazz Pharmaceuticals Completes Acquisition of Chimerix
Details : Through the acquisition, Jazz will strengthen it's oncology pipeline, which includes ONC201 (dordaviprone). It is being evaluated in the late-stage for the treatment of H3 K27M-mutant diffuse glioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $935.0 million
April 21, 2025
Details:
Through the acquisition, Jazz will strengthen it's oncology pipeline, which includes ONC201 (dordaviprone). It is being in the evaluated late-stage for the treatment of H3 K27M-mutant diffuse glioma.
Lead Product(s): Dordaviprone,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Jazz Pharmaceuticals
Deal Size: $935.0 million Upfront Cash: $935.0 million
Deal Type: Acquisition March 05, 2025
Lead Product(s) : Dordaviprone,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Jazz Pharmaceuticals
Deal Size : $935.0 million
Deal Type : Acquisition
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
Details : Through the acquisition, Jazz will strengthen it's oncology pipeline, which includes ONC201 (dordaviprone). It is being in the evaluated late-stage for the treatment of H3 K27M-mutant diffuse glioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $935.0 million
March 05, 2025
Details:
ONC201 (dordaviprone) is a novel first-in-class small molecule imipridone that selectively targets the mitochondrial protease ClpP and dopamine receptor D2 for recurrent H3 K27M-Mutant diffuse glioma.
Lead Product(s): Dordaviprone,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 18, 2025
Lead Product(s) : Dordaviprone,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Chimerix Announces FDA Acceptance and Priority Review of NDA for Dordaviprone
Details : ONC201 (dordaviprone) is a novel first-in-class small molecule imipridone that selectively targets the mitochondrial protease ClpP and dopamine receptor D2 for recurrent H3 K27M-Mutant diffuse glioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 18, 2025
Details:
ONC201 (dordaviprone) is a novel first-in-class small molecule imipridone that selectively targets the mitochondrial protease ClpP and dopamine receptor D2 for recurrent H3 K27M-Mutant diffuse glioma.
Lead Product(s): Dordaviprone,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 30, 2024
Lead Product(s) : Dordaviprone,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Chimerix Submits Dordaviprone NDA for Accelerated Approval Of Recurrent Diffuse Glioma
Details : ONC201 (dordaviprone) is a novel first-in-class small molecule imipridone that selectively targets the mitochondrial protease ClpP and dopamine receptor D2 for recurrent H3 K27M-Mutant diffuse glioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 30, 2024
Details:
ONC201 (dordaviprone) targets the targets the mitochondrial protease ClpP and dopamine receptor D2. It is being evaluated for the treatment of recurrent H3 K27M-mutant diffuse glioma.
Lead Product(s): Dordaviprone,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 09, 2024
Lead Product(s) : Dordaviprone,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Chimerix to Submit Dordaviprone for Accelerated Approval in for H3 K27M-Mutant Glioma
Details : ONC201 (dordaviprone) targets the targets the mitochondrial protease ClpP and dopamine receptor D2. It is being evaluated for the treatment of recurrent H3 K27M-mutant diffuse glioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 09, 2024
Details:
ONC201 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Meningioma.
Lead Product(s): Dordaviprone,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Chimerix
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 28, 2023
Lead Product(s) : Dordaviprone,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Chimerix
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of ONC201 for Refractory Meningioma
Details : ONC201 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Meningioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 28, 2023
Details:
ONC201 is a new drug candidate that kills cancer cells but not normal cells in laboratory studies and has been previously evaluated in a phase I clinical trial in advanced cancer patients.
Lead Product(s): Dordaviprone,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 08, 2022
Lead Product(s) : Dordaviprone,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ONC201 is a new drug candidate that kills cancer cells but not normal cells in laboratory studies and has been previously evaluated in a phase I clinical trial in advanced cancer patients.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 08, 2022
Details:
Dordaviprone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Glioma.
Lead Product(s): Dordaviprone,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 14, 2022
Lead Product(s) : Dordaviprone,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
Details : Dordaviprone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Glioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 14, 2022
Details:
Atezolizumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Endometrial Neoplasms.
Lead Product(s): Atezolizumab,Dordaviprone
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Genentech | Oncoceutics Inc | National Cancer Institute
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 15, 2022
Lead Product(s) : Atezolizumab,Dordaviprone
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Genentech | Oncoceutics Inc | National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
Details : Atezolizumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Endometrial Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 15, 2022
Details:
ONC201 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diffuse Intrinsic Pontine Glioma.
Lead Product(s): Dordaviprone,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Chimerix | Innovative Therapies for Children with Cancer Consortium | Ministry of Health, France
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 27, 2022
Lead Product(s) : Dordaviprone,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Chimerix | Innovative Therapies for Children with Cancer Consortium | Ministry of Health, France
Deal Size : Inapplicable
Deal Type : Inapplicable
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
Details : ONC201 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diffuse Intrinsic Pontine Glioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 27, 2022
Regulatory Info : RX
Registration Country : USA
Brand Name : MODEYSO
Dosage Form : CAPSULE;ORAL
Dosage Strength : EQ 125MG BASE
Packaging :
Approval Date : 2025-08-06
Application Number : 219876
Regulatory Info : RX
Registration Country : USA
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
82
PharmaCompass offers a list of Dordaviprone API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Dordaviprone manufacturer or Dordaviprone supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dordaviprone manufacturer or Dordaviprone supplier.
PharmaCompass also assists you with knowing the Dordaviprone API Price utilized in the formulation of products. Dordaviprone API Price is not always fixed or binding as the Dordaviprone Price is obtained through a variety of data sources. The Dordaviprone Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Dordaviprone manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dordaviprone, including repackagers and relabelers. The FDA regulates Dordaviprone manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dordaviprone API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Dordaviprone supplier is an individual or a company that provides Dordaviprone active pharmaceutical ingredient (API) or Dordaviprone finished formulations upon request. The Dordaviprone suppliers may include Dordaviprone API manufacturers, exporters, distributors and traders.
Dordaviprone Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dordaviprone GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dordaviprone GMP manufacturer or Dordaviprone GMP API supplier for your needs.
A Dordaviprone CoA (Certificate of Analysis) is a formal document that attests to Dordaviprone's compliance with Dordaviprone specifications and serves as a tool for batch-level quality control.
Dordaviprone CoA mostly includes findings from lab analyses of a specific batch. For each Dordaviprone CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dordaviprone may be tested according to a variety of international standards, such as European Pharmacopoeia (Dordaviprone EP), Dordaviprone JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dordaviprone USP).